Fluvoxamine in Long COVID
Phase 3
- Conditions
- ong or Post COVID syndrome.Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis.U09.9
- Registration Number
- IRCT20220526054990N1
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Confirmed COVID infection by infectious disease specialist
Age over 15 years
Exclusion Criteria
History of epilepsy
History of mania
History of depression
Use of other antidepressants
Pregnancy and lactationK
Kidney dysfunction
Liver dysfunction
History of cardiac arrhythmia
Any drug allergy to fluvoxamine, including skin allergies
Severe side effects of fluvoxamine, including malignant neuroleptic syndrome
Drug interactions with other drugs consumed by the patient
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of any of the neuropsycological symptoms of Long COVID in patients. Timepoint: 4 weeks after COVID symptoms onset. Method of measurement: history taking based on a questionnaire prepared by the researcher.
- Secondary Outcome Measures
Name Time Method